Sperogenix Therapeutics Limited Homepage | 曙方医药集团北京罕友医药有限公司官方网站

GET TO KNOW US

KNOW

About us

Sperogenix Therapeutics is a platform company dedicated to developing and commercializing rare disease therapeutics in China. With prioritized therapeutic areas, such as pulmonary vascular disorders, neuromuscular diseases, and inherited metabolic diseases, Sperogenix is dedicated to establishing an innovative commercial model tailored to the China rare disease field, in order to provide affordable and reliable products and services to Chinese physicians and patients. Sperogenix was founded in 2019 and is backed by biopharma industry blue chip investors including Lilly Asia Ventures and Morningside Ventures.

Vision, Mission & Values

Vision

Strive to become the respected leading rare diseases company with commercial success in China

Mission

Committed to providing advanced products and solutions for Chinese rare diseases patients, narrowing the gap between China and developed countries and regions in diagnosis and treatment, and meeting the unmet medical needs in the field of rare diseases in China.

Values

Patients and physicians centerd. High standard of responsibility and ethics. Unremitting learning and innovation

Strategies

BUSINESS DEVELOPMENT

Meet the huge unmet demands with advanced treatment

CLINICAL DEVELOPMENT

Accelerate both global and local product approval and launch

CUSTOMER ENGAGEMENT

Establish a promising future for product value maximization

Scientific Advisory Board

Hanlan LIU PhD., MBA

Renato SKERLJ PhD.

Executive Management

Co-Founder, Chairman & Chief Executive Officer

Co-Founder, Chief Commercial and Operating Officer

Qiuqing ANG MD., PhD.

Chief Medical Officer

Investors

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. LAV's vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.

Morningside Ventures

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.